Chimerism does not predict for outcome after alemtuzumab-based conditioning: lineage-specific analysis of chimerism of specific diseases may be more informative

Bone Marrow Transplant. 2008 Mar;41(6):587-8. doi: 10.1038/sj.bmt.1705937. Epub 2007 Nov 26.

Authors

Z Y Lim, L Pearce, W Ingram, A Y L Ho, G J Mufti, A Pagliuca

PMID: 18037939
DOI: 10.1038/sj.bmt.1705937

No abstract available

Publication types

Letter
Comment

MeSH terms

Alemtuzumab
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm / administration & dosage
Antineoplastic Agents / administration & dosage
Hematopoietic Stem Cell Transplantation*
Humans
Leukemia, Myeloid, Acute / mortality
Leukemia, Myeloid, Acute / therapy
Leukocytes / immunology
Microsatellite Repeats / genetics
Myelodysplastic Syndromes / mortality
Myelodysplastic Syndromes / therapy
Predictive Value of Tests
Retrospective Studies
Tissue Donors
Transplantation Chimera*
Transplantation Conditioning*
Transplantation, Homologous
Treatment Outcome

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm
Antineoplastic Agents
Alemtuzumab